Efficacy and safety of antigen-specific immunotherapy in the treatment of patients with non-small-cell lung cancer: a systematic review and meta-analysis.

Related Articles

Efficacy and safety of antigen-specific immunotherapy in the treatment of patients with non-small-cell lung cancer: a systematic review and meta-analysis.

Curr Cancer Drug Targets. 2018 Apr 30;:

Authors: Yan BD, Cong XF, Zhao SS, Ren M, Liu ZL, Li Z, Chen C, Yang L

Abstract
BACKGROUND AND OBJECTIVE: We performed this systematic review and meta-analysis to assess the efficacy and safety of antigen-specific immunotherapy (Belagenpumatucel-L, MAGE-A3, L-BLP25, and TG4010) in the treatment of patients with non-small-cell lung cancer (NSCLC).
METHOD: A comprehensive literature search on PubMed, Embase, and Web of Science were conducted. Eligible studies were clinical trials of patients with NSCLC who received the antigen-specific immunotherapy. Pooled hazard ratios (HRs) with 95% confidence intervals (95%CIs) were calculated for overall survival (OS), progression free survival (PFS). Pooled risk ratios (RRs) were calculated for overall response rate (ORR) and the incidence of adverse events.
RESULTS: In total, six randomized controlled trials (RCTs) with 4,806 patients were included. Pooled results showed that, antigen-specific immunotherapy did not significantly prolong OS (HR=0.92, 95%CI: 0.83, 1.01; P=0.087) and PFS (HR=0.93, 95%CI: 0.85, 1.01; P=0.088), but improved ORR (RR=1.72, 95%CI: 1.11, 2.68; P=0.016). Subgroup analysis based on treatment agents showed that, tecemotide was associated with a significant improvement in OS (HR=0.85, 95%CI: 0.74, 0.99; P=0.03) and PFS (HR=0.70, 95%CI: 0.49, 0.99, P=0.044); TG4010 was associated with an improvement in PFS (HR=0.87, 95%CI: 0.75, 1.00, P=0.058). In addition, NSCLC patients who were treated with antigen-specific immunotherapy exhibited a significantly higher incidence of adverse events than those treated with other treatments (RR=1.11, 95%CI: 1.00, 1.24; P=0.046).
CONCLUSION: Our study demonstrated the clinical survival benefits of tecemotide and TG4010 in the treatment of NSCLC. However, these evidences might be limited by potential biases. Therefore, further well-conducted, large-scale RCTs are needed to verify our findings.

PMID: 29714142 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader https://ift.tt/2KtF2Gk
via IFTTT